share_log

Nurix Therapeutics (NASDAQ:NRIX) Shares Gap Up to $10.26

Nurix Therapeutics (NASDAQ:NRIX) Shares Gap Up to $10.26

努里克治療學（NASDAQ：NRIX）股份差距高達 10.26 美元
Defense World ·  2023/01/12 04:42

Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Rating) gapped up prior to trading on Tuesday . The stock had previously closed at $10.26, but opened at $10.67. Nurix Therapeutics shares last traded at $10.75, with a volume of 316 shares changing hands.

NURIX 治療公司（NASDAQ：NRIX — 獲得評級）在星期二交易之前突破了。該股票之前已收盤 10.26 美元，但收盤價為 10.67 美元。NURIX 治療學的股票最後交易價為 10.75 美元，成交量為 316 股。

Analysts Set New Price Targets

分析師設定新的價格目標

Several research firms have recently weighed in on NRIX. Morgan Stanley began coverage on Nurix Therapeutics in a research report on Tuesday, October 11th. They issued an "equal weight" rating and a $11.00 target price on the stock. HC Wainwright decreased their target price on Nurix Therapeutics to $53.00 in a research report on Thursday, October 13th. Finally, SVB Leerink decreased their target price on Nurix Therapeutics from $37.00 to $28.00 and set an "outperform" rating on the stock in a research report on Tuesday, December 13th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Nurix Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $32.90.

幾家研究公司最近對 NRIX 進行了重視。摩根士丹利於 10 月 11 日（星期二）在一份研究報告中開始對 Nurix 治療學進行報導。他們對股票發出了「同等權重」評級和 11.00 美元的目標價。韋賴特在 10 月 13 日（星期四）的一份研究報告中，HC 溫賴特將其對 NURIX 治療的目標價格降至 $53.00。最後，SVB 萊林克將其在 Nurix 治療的目標價格從 37.00 美元降至 28.00 美元，並在 12 月 13 日（星期二）的一份研究報告中設定了該股票的「跑贏大市」評級。一位投資分析師已將該股票評級為持有評級，而七位則為該股指定了買入評級。根據 MarketBeat.com 的數據，努里克治療目前的平均評級為「適度買入」，平均目標價為 32.90 美元。

Get
取得
Nurix Therapeutics
努里斯治療學
alerts:
警報：

Nurix Therapeutics Price Performance

努里斯治療學價格表現

The stock has a market cap of $533.24 million, a price-to-earnings ratio of -3.05 and a beta of 1.63. The firm has a fifty day moving average of $11.93 and a 200 day moving average of $13.70.

該股的市值為 53,324 萬美元，價格與收益比為 -3.05，測試版為 1.63。該公司有一個五十天移動平均線 11.93 美元和 200 日移動平均線為 13.70 美元。

Institutional Investors Weigh In On Nurix Therapeutics

機構投資者權衡 Nurix 治療

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. increased its stake in Nurix Therapeutics by 11.0% during the third quarter. BlackRock Inc. now owns 3,723,090 shares of the company's stock worth $48,512,000 after acquiring an additional 367,743 shares during the last quarter. State Street Corp increased its stake in Nurix Therapeutics by 9.2% during the third quarter. State Street Corp now owns 2,312,224 shares of the company's stock worth $30,128,000 after acquiring an additional 195,453 shares during the last quarter. Vanguard Group Inc. increased its stake in Nurix Therapeutics by 2.3% during the third quarter. Vanguard Group Inc. now owns 2,160,866 shares of the company's stock worth $28,156,000 after acquiring an additional 49,370 shares during the last quarter. Bain Capital Life Sciences Investors LLC increased its stake in Nurix Therapeutics by 41.9% during the second quarter. Bain Capital Life Sciences Investors LLC now owns 1,822,883 shares of the company's stock worth $23,096,000 after acquiring an additional 538,570 shares during the last quarter. Finally, FMR LLC increased its stake in Nurix Therapeutics by 59.6% during the second quarter. FMR LLC now owns 1,790,655 shares of the company's stock worth $22,688,000 after acquiring an additional 668,632 shares during the last quarter. Institutional investors and hedge funds own 91.33% of the company's stock.
幾家對沖基金和其他機構投資者最近更改了他們在股票中的頭寸。在第三季度，貝萊德公司在 Nurix 治療學的股份增加了 11.0%。在上一季度增加 367,743 股後，貝萊德公司現在擁有該公司股票 3,723,090 股，價值 48,512,000 美元。在第三季度，州街公司將其在 Nurix 治療學的股份增加了 9.2％。州街公司現在擁有該公司股票的 2,312,224 股股票，價值 30,128,000 美元，在上一季度額外購買 195,453 股後。先鋒集團在第三季度將其在 NURIX 治療的股份增加了 2.3％。領航集團股份有限公司在上一季度額外收購 49,370 股股份後，擁有該公司股票價值 28,156,000 美元的 2,160,866 股股份。貝恩資本生命科學投資者有限責任公司在第二季度將其在 Nurix 治療的股份增加了 41.9％。貝恩資本生命科學投資者有限責任公司現在擁有該公司股票的 1,822,883 股價值 23,096,000 美元，在上一季度額外收購 538,570 股股票後。最後，FMR 有限責任公司在第二季度將其在 NURIX 治療學的股份增加了 59.6％。在上一季度額外購買 668,632 股股票後，FMR 有限責任公司現在擁有該公司股票的 1,790,655 股價值 22,688,000 美元。機構投資者和對沖基金擁有公司股票的 91.33％。

Nurix Therapeutics Company Profile

努里斯治療公司簡介

(Get Rating)

(取得評分)

Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

Nurix Therapitics, Inc 是一家生物製藥公司，專注於用於治療癌症和免疫疾病的小分子療法的發現、開發和商業化。該公司開發出口服布魯頓酪氨酸激酶（BTK）降解劑 NX-2127，用於治療復發或難治 B 細胞惡性腫瘤；NX-5948，一種口服生物利用 BTK 降解劑，用於治療復發或難治 B 細胞惡性腫瘤和自身免疫性疾病的；以及用於治療 B 型腫瘤（B 型腫瘤）乳癌性腫瘤（B 型腫瘤）的口服生物利用性 BTK 降解劑（）用於腫瘤免疫適應症的 CBL-B）抑製劑。NX-1607

Featured Articles

特色文章

  • Get a free copy of the StockNews.com research report on Nurix Therapeutics (NRIX)
  • Bloom Energy Powers Up After an Upgrade, is it Worth the Risk?
  • Why Hershey Is a Sweet Recession Stock
  • Will Amazon Stock Be Delivering for Investors in 2023?
  • The Analysts Shift Trucking Sentiment Back into Forward
  • The Institutions Book A Flight With Boeing
  • 獲取有關紐瑞斯治療學（NRIX）的研究報告的免費副本
  • 綻放能量升級後，值得冒險嗎？
  • 為什麼赫爾希是一個甜蜜的經濟衰退股票
  • 亞馬遜股票會在 2023 年為投資者交付嗎？
  • 分析師將卡車情緒轉向前
  • 機構與波音公司預訂航班

Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

每日接收 Nurix 治療學的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關 Nurix 治療及相關公司的最新新聞和分析師評級的簡要每日摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論